Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrina Chiloiro

Showing results (11-20 of 117) with videos related to

Pageof 12
Sort By:
Protein and Peptide Letters|December 6, 2019
Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic ReviewBrigida Anna Maiorano, Giovanni Schinzari, Sabrina Chiloiro, et al.
Endocrine|February 22, 2023
De-escalation treatment with pasireotide for acromegaly: a long-term experienceAntonella Giampietro, Sara Menotti, Sabrina Chiloiro, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|August 5, 2022
Second line treatment of acromegaly: Pasireotide or Pegvisomant?Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, et al.
Trends in Endocrinology and Metabolism: TEM|December 13, 2021
The changing clinical spectrum of endocrine adverse events in cancer immunotherapySabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, et al.
Pituitary|December 31, 2024
Empty sella syndrome: an updateFrancesco Padovano Sorrentino, Sabrina Chiloiro, Antonella Giampietro, et al.
Endocrine|January 10, 2018
Bone safety of dual-release hydrocortisone in patients with hypopituitarismStefano Frara, Sabrina Chiloiro, Teresa Porcelli, et al.
Reviews in Endocrine & Metabolic Disorders|March 15, 2025
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registriesLuigi Demarchis, Sabrina Chiloiro, Antonella Giampietro, et al.
Pituitary|November 8, 2025
Acromegaly treatment and bone: a bidirectional relationshipSabrina Chiloiro, Chiara Palumbo, Antonella Giampietro, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 10, 2024
The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First-generation SSAs and Treated with Pegvisomant or Pasireotide LARFlavia Costanza, Sabrina Chiloiro, Antonella Giampietro, et al.
Pituitary|March 31, 2026
To test or not to test: what we have learnt from 50 years of dynamic testing in acromegalyLaura De Marinis, Sabrina Chiloiro, Antonio Mancini, et al.
Pageof 12

Showing results (11-20 of 117) with videos related to

Sort By:
Pageof 12
Protein and Peptide Letters|December 6, 2019
Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic ReviewBrigida Anna Maiorano, Giovanni Schinzari, Sabrina Chiloiro, et al.
Endocrine|February 22, 2023
De-escalation treatment with pasireotide for acromegaly: a long-term experienceAntonella Giampietro, Sara Menotti, Sabrina Chiloiro, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|August 5, 2022
Second line treatment of acromegaly: Pasireotide or Pegvisomant?Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, et al.
Trends in Endocrinology and Metabolism: TEM|December 13, 2021
The changing clinical spectrum of endocrine adverse events in cancer immunotherapySabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, et al.
Pituitary|December 31, 2024
Empty sella syndrome: an updateFrancesco Padovano Sorrentino, Sabrina Chiloiro, Antonella Giampietro, et al.
Endocrine|January 10, 2018
Bone safety of dual-release hydrocortisone in patients with hypopituitarismStefano Frara, Sabrina Chiloiro, Teresa Porcelli, et al.
Reviews in Endocrine & Metabolic Disorders|March 15, 2025
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registriesLuigi Demarchis, Sabrina Chiloiro, Antonella Giampietro, et al.
Pituitary|November 8, 2025
Acromegaly treatment and bone: a bidirectional relationshipSabrina Chiloiro, Chiara Palumbo, Antonella Giampietro, et al.
Endocrine, Metabolic & Immune Disorders Drug Targets|July 10, 2024
The Role of the GH Receptor Polymorphisms as a Prognostic Factor of Vertebral Fractures in Acromegalic Patients Resistant to First-generation SSAs and Treated with Pegvisomant or Pasireotide LARFlavia Costanza, Sabrina Chiloiro, Antonella Giampietro, et al.
Pituitary|March 31, 2026
To test or not to test: what we have learnt from 50 years of dynamic testing in acromegalyLaura De Marinis, Sabrina Chiloiro, Antonio Mancini, et al.
Pageof 12